Table 1 Patient and tumour characteristics according to treatment
Variable | Tamoxifen treated patients (n=123) | Control (n=125) |
|---|---|---|
Age (years) median | 66.2 (54.9–74.7) | 66.8 (55.2–74.9) |
Age (number) | ||
>Median 66 years | 60 | 65 |
<Median 66 years | 63 | 60 |
Tumour size | ||
Median (mm) | 25.0 (3–55) | 24.5 (>0–76) |
Size not known | 2 | 0 |
Node status | ||
Node− | 80 | 79 |
Node+ | 41 | 45 |
Not known | 2 | 1 |
Stage | ||
I | 30 | 35 |
II | 90 | 85 |
III | 1 | 4 |
Not known | 2 | 1 |
ERα fraction | ||
0–10% | 19 | 29 |
10–90% | 14 | 12 |
>90% | 53 | 55 |
Not known | 37 (30%) | 29 (23%) |
PR fraction | ||
0–10% | 47 | 50 |
10–90% | 20 | 22 |
>90% | 17 | 18 |
Not known | 39 (32%) | 35 (28%) |
Cyclin D1 fraction | ||
0–10% | 21 | 21 |
10–90% | 53 | 53 |
>90% | 9 | 15 |
Not known | 40 (33%) | 36 (29%) |
Cyclin D1 intensity | ||
Negative | 0 | 1 |
Low | 4 | 5 |
Moderate | 50 | 49 |
High | 29 | 34 |
Not known | 40 (33%) | 36 (29%) |
10-year FU | ||
Alive | 76 | 72 |
Dead | 47 | 53 |
Maximum FU | ||
Alive | 42 | 42 |
Dead | 81 | 83 |
